<DOC>
	<DOCNO>NCT02560441</DOCNO>
	<brief_summary>The first Part : recruiting untreated ENKL patient extensive stage I limit stage II disease ( refer patient invasion Waldeyer 's ring cervical lymph node ) . Patients randomly divide two arm , IPGDP regimen chemotherapy follow radiotherapy radiotherapy follow IPGDP regimen chemotherapy . IPGDP regimen arm 3 cycle . And chemotherapy repeat every 3 weeks.. The second part : recruiting extensive stage II , stage III-IV , relapse refractory ENKL patient . Patients receive 6 cycle IPGDP regimen chemotherapy . And chemotherapy repeat every 3 week .</brief_summary>
	<brief_title>Trial IPGDP Regimen Chemotherapy Patients With Extranodal Natural Killer/T-Cell Lymphoma , Nasal Type</brief_title>
	<detailed_description>The first Part : Patients IPGDP regimen chemotherapy follow radiotherapy arm receive 3 cycle IPGDP ( ifosfamide 1.2g/m2 iv day 3-5 ; pegaspargase 2000U/m2 im day 1 ; gemcitabine 800mg/m2 iv day 3,8 ; cisplatin 25 mg/m2 iv day 3-5 ; dexamethasone 20mg/m2 iv day 3-6 ) chemotherapy . Then patient undergo radiotherapy . If disease consider progress stable chemotherapy , patient directly receive radiotherapy . Patients another arm receive radiotherapy follow IPGDP regimen chemotherapy . IPGDP regimen arm 3 cycle , repeat every 3 week . The second Part : Patients receive 6 cycle ifosfamide 1.2g/m2 iv day 3-5 ; pegaspargase 2000U/m2 im day 1 ; gemcitabine 800mg/m2 iv day 3,8 ; cisplatin 25 mg/m2 iv day 3-5 ; dexamethasone 20mg/m2 iv day 3-6 . IPGDP regimen repeat every 3 week . If disease consider progress stable 2 cycle 4 cycle chemotherapy , patient withdraw study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<criteria>histologically proven diagnosis Extranodal Natural Killer/TCell Lymphoma , Nasal Type ( ENKL ) untreated ENKL patient extensive stage I limit stage II ( refer patient invasion Waldeyer 's ring neck lymph node ) confirm imaging examination ; extensive stage II , stage IIIIV , relapse refractory ENKL patient confirm image examination age 1865 year least one measurable lesion Eastern Cooperative Oncology Group ( ECOG ) 0 1 life expectancy least 12 week Adequate organ function include follow : Bone marrow : absolute neutrophil count ( ANC ) &gt; equal 1.5 * 109/L , platelet &gt; equal 100 *109/L , hemoglobin &gt; equal 9g/dL . Hepatic : bilirubin &lt; equal 2 x ULN ; aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; equal 2.5 x ULN ( AST , ALT &lt; equal 5 x ULN acceptable liver involve ) . Renal : serum creatinine &lt; equal 1.5 x ULN . Coagulation function : activate partial thromboplastin time &lt; equal 1.5 x ULN , fibrinogen &gt; equal 0.75 time low limit normal value , INR &lt; equal 1.5 x ULN . inform consent sign patient prior commencement study pregnancy test Women childbearing must negative begin 7 day treatment ; surgical sterilization take contraceptive measure treatment three month end treatment male . severe allergy investigational drug patient receive unauthorized drug drug trial within 4 week prior study Severe unstable systemic disease，serious neurological psychiatric disease include seizure dementia organ function include follow : Bone marrow : absolute neutrophil count ( ANC ) ＜ 1.5 * 109/L , platelets＜100 *109/L , hemoglobin ＜ 9g/dL . Hepatic : bilirubin &gt; 2 x ULN ; aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 2.5 x ULN ( AST , ALT &gt; 5 x ULN acceptable liver involve ) . Renal : serum creatinine &gt; 1.5 x ULN . Abnormal Coagulation function : activate partial thromboplastin time prolong &gt; 1.5 x ULN , fibrinogen &lt; 0.75 time low limit normal value , increase INR &gt; 1.5 x ULN important clinical laboratory abnormality appropriate research Patients previously receive treatment study , withdraw study receive antitumor therapy time pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>